Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

otide (MBP8298)

--------------------------

Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The drug's apparent mechanism of action is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

Dirucotide (MBP8298) is being studied in four late-stage clinical trials:

- MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

- MAESTRO-02: An open-label safety extension study to MAESTRO-01.

- MAESTRO-03: A pivotal phase III trial for SPMS patients
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... og SHENZHEN , Kina, ... Co., LTD, (BGI Tech), et datterselskab af BGI, ... en ny human whole exome-sekvenseringstjeneste baseret på Complete ... højt anset i branchen for at levere patenterede ... af alle typer varianter, blev købt af BGI ...
(Date:7/22/2014)... China , 22 juli 2014 BGI ... BGI, ,s wereld grootste organisatie op het gebied van ... service ten behoeve van hele menselijke genoomsequentie via het ... In 2013 acquireerde BGI Complete Genomics, ... staat vanwege de in eigen beheer ontwikkelde sequentietechnologieën met ...
(Date:7/22/2014)... -- Hussey Copper , a leader in copper ... announces Pullman Regional Hospital,s conversion of more than 1,100 ... surface, at a nominal cost.  This reasonably priced surface ... bacteria within 2 hours of exposure 1 and will ... diseases in its facilities. Pullman Regional Hospital, ...
(Date:7/22/2014)... 2014  Semler Scientific, Inc. (Nasdaq: ... company that develops patented products that assist healthcare ... today announced that it will report second quarter ... financial markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief ... call at 11 a.m. EDT, July 25, 2014. ...
Breaking Biology Technology:BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... Bunge North America, the North American operating arm of Bunge ... which can be attributed to Soren Schroder, Bunge North America ... aware from press reports of Syngenta,s allegations.  From what we ... and disappointed that Syngenta has taken an action which could ...
... 23, 2011 MedNet Solutions, a global life sciences technology ... to announce that MedNet has once again been recognized by ... held companies in the United States.  MedNet is greatly honored ... straight year, since, as noted by Inc . magazine, ...
... FMC Corporation (NYSE: FMC ) announced today ... agreements covering global development and supply of Chr. Hansen ... begin commercialization this year of Chr. Hansen,s Nemix bacillus ... standalone and combination products in the Americas and key ...
Cached Biology Technology:Bunge Responds to Syngenta Suit 2MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row 2FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2
(Date:7/23/2014)... for providing essential fatty acids and energy to ... has been concern that soybean-based emulsions could compromise ... its composition. Combination lipid emulsions based on triglyceride ... developed to address this concern. , However, researchers ... may be unwarranted, according to a review published ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2014. Revenue for the ... 53% compared to $4.4 million in the same quarter last ... quarter of 2014 was $1.4 million compared to $0.5 million ... and operating income was driven by higher sales of software ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... , June 19, 2013  Paris Air Show – ... Systems) , a leading provider of innovative test solutions ... solutions this week at the Paris Air Show ... complex armament systems with longer lifecycles, industry leaders are ...
... University, sophisticated computational models and advances in graphical processing ... genomic data, virus structure and the formation of the ... "We hope that some of what we are ... unable to replicate," says post-doctoral fellow Jason Perlmutter, first ...
... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ...
Cached Biology News:Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Computer modeling technique goes viral at Brandeis 2The American Society for Microbiology honors Joshua Obar 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
... 500 reactions. Prepare circular DNA templates ... microgram quantities of template DNA from ... DNA directly for cycle sequencing without ... liquid cultures, colonies, plaques, or purified ...
...
Biology Products: